Nomura Adjusts WuXi AppTec's Price Target to HK$43.45 From HK$54.56, Keeps at Buy
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$23.25 From HK$53.65, Keeps at Buy
Nomura Adjusts Hansoh Pharmaceutical's Price Target to HK$17.23 From HK$15.03, Keeps at Neutral
Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$9.83 From HK$10.07, Keeps at Buy
Nomura Adjusts Akeso's Price Target to HK$46.04 From HK$52.80, Keeps at Buy
Nomura Adjusts Innovent Biologics' Price Target to HK$55.87 From HK$55.31, Keeps at Buy
Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target Is HK$14
Analysts' Opinions Are Mixed on These Healthcare Stocks: Carl Zeiss Meditec (GB:0DHC), Akeso, Inc. (HK:9926) and Almirall (GB:0O9B)
Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$10.07 From HK$9.41, Keeps at Buy
Nomura Adjusts Wuxi Apptec's Price Target to 62.75 Yuan From 99.16 Yuan, Keeps at Buy
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.16 From HK$6.63, Keeps at Buy
Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$9.41 From HK$8.98, Keeps at Buy
Nomura Adjusts Wuxi Biologics' Price Target to HK$53.65 From HK$58.44, Keeps at Buy
Nomura Adjusts Innovent Biologics' Price Target to HK$55.31 From HK$54.51, Keeps at Buy
Nomura Adjusts Akeso's Price Target to HK$52.80 From HK$48.84, Keeps at Buy
Nomura Adjusts Wuxi Biologics' Price Target to HK$58.44 From HK$82.69, Keeps at Buy
Nomura Adjusts Innovent Biologics' Price Target to HK$54.51 From HK$45.73, Keeps at Buy
INNOVENT BIOLOGICS(1801.HK):MAZDUTIDE(9MG)CONTINUES TO SHOW ITS BIC POTENTIAL WITH 48-WEEK RESULTS
Nomura Adjusts Wuxi Apptec's Price Target to HK$121.70 From HK$98.96, Keeps at Buy
Nomura Adjusts Wuxi Apptec's Price Target to 139.96 Yuan From 113.43 Yuan, Keeps at Buy